Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

  • In development
  • GID-TA11100
  • Expected publication date: 

Documents

Documents created during the development process.

Committee meetings

  • Committee meeting

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6304

Notes